Category: AHFS PMI

AHFS Patient Medication Information Update – July 2017

10 August, 2017 no responses

The July update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Naldemedine (Symproic®)
    • Naldemedine is used to treat constipation caused by opioid (narcotic) pain medications in adults with chronic (ongoing) pain that is not caused by cancer.
  • Ammonium Lactate Topical (Lac-Hydrin®)
    • Ammonium lactate is used to treat xerosis (dry or scaly skin) and ichthyosis vulgaris (an inherited dry skin condition) in adults and children.
  • Telotristat (Xermelo®)
    • Telotristat is used in combination with another medication (a samotostatin analog [SSA] such as lanreotide, octreotide, pasinreotide) to control diarrhea caused by carcinoid tumors (slow-growing tumors that release natural substances that can cause symptoms like diarrhea) in patients with diarrhea not controlled by a somatostatin analog alone.
  • Durvalumab Injection (Imfinzi®)
    • Durvalumab injection is used to treat urothelial cancer (cancer of the lining of the bladder and other parts of the urinary tract) that spread to nearby tissues or other parts of the body that cannot be removed by surgery and has worsened during or after being treated with other chemotherapy medications.

FDA MedWatch Alert Revisions

  • None

AHFS Patient Medication Information Update – June 2017

30 June, 2017 no responses

The June update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Ocrelizumab Injection (Ocrevus®)
    • Ocrelizumab injection is used to treat adults with relapsing-remitting forms (course of disease where symptoms flare up from time to time) or primary-progressive forms (symptoms gradually become worse over time) of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control).
  • Valbenazine (Ingrezza®)
    • Valbenazine is used to treat tardive dyskinesia (uncontrollable movement of the face, tongue, or other body parts).
  • Deutetrabenazine (Austedo®)
    • Deutetrabenazine is used to treat chorea (sudden movements that you cannot control) caused by Huntington’s disease (an inherited disease that causes the progressive breakdown of nerve cells in the brain).
  • Safinamide (Xadago®)
    • Safinamide is used along with the combination of levodopa and carbidopa (Duopa, Rytary, Sinemet, others) to treat “off” episodes (times of difficulty moving, walking, and speaking that may happen as medication wears off or at random) in people with Parkinson’s disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance).
  • Deflazacort (Emflaza®)
    • Deflazacort is used to treat Duchenne muscular dystrophy (DMD; a progressive disease in which the muscles do not function properly) in adults and children 5 years of age and older.
  • Dupilumab Injection (Dupixent®)
    • Dupilumab injection is used to treat the symptoms of eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in people who cannot use other medications for their condition or whose eczema has not responded to other medications.
  • Plecanatide (Trulance®)
    • Plecanatide is used in adults to treat chronic idiopathic constipation (CIC; difficult or infrequent passage of stools that lasts for 3 months or longer and is not caused by a disease or a medication).
  • Crisaborole Topical (Eucrisa®)
    • Crisaborole is used to treat eczema (atopic dermatitis; a skin condition which causes the skin to be dry and itchy and to sometimes develop red, scaly rashes).
  • Oxymetazoline Topical (Rhofade®)
    • Oxymetazoline is used to treat ongoing facial redness caused by rosacea (a skin disease that causes redness and pimples on the face).

FDA MedWatch Alert Revisions

  • FDA is requiring new warnings, including the most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.
    • Based on new data from two large clinical trials, the FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations.
    • Affected Monographs:
      • Canagliflozin

AHFS Patient Medication Information Update – May 2017

24 May, 2017 no responses

The May update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Ribociclib (Kisqali®)
    • Ribociclib is used in combination with another medication to treat a certain type of hormone receptor–positive, advanced breast cancer breast cancer that depends on hormones such as estrogen to grow) in women who have experienced menopause (change of life; end of monthly menstrual periods).
  • Niraparib (Zejula®)
    • Niraparib is used to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the stomach) cancer to chemotherapy medications after the cancer has returned from previous treatment(s).
  • Avelumab Injection (Bavencio®)
    • Avelumab injection is used to treat a certain type of skin cancer that has spread to other parts of the body in adults and children 12 years of age and older.

FDA MedWatch Alert Revisions

  • FDA is restricting the use of codeine and tramadol medicines in children.
    • These medicines carry serious risks, including slowed or difficult breathing and death, which appear to be a greater risk in children younger than 12 years, and should not be used in these children.
    • Affected Monographs:
      • Acetaminophen and Codeine
      • Acetaminophen, Butalbital, and Caffeine
      • Codeine
      • Tramadol
  • FDA has approved previously announced label changes regarding the use of general anesthetic and sedation medicines in children younger than 3 years.
    • Affected Monographs:
      • Midazolam
1 2 3 4 5
© 2022, American Society of Health-System Pharmacists®. All rights reserved.